Education
About Us
Working with TipRanks
Follow Us
TripSitter Clinic Ltd (TSE:KETA)
:KETA
Top Page
TripSitter Clinic Ltd
(KETA)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.05
▼(-11.67% Downside)
The score is driven down primarily by severe financial weakness (near-zero revenue, ongoing losses, and negative equity indicating elevated solvency/funding risk). Technicals also remain bearish with the stock trading below key moving averages and negative MACD, while valuation offers limited support given losses (negative P/E) and no dividend.
TripSitter Clinic Ltd (KETA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$366.20K
Dividend YieldN/A
Average Volume (3M)1.71K
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding6,658,174
10 Day Avg. Volume150
30 Day Avg. Volume1,705
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-0.36
Price to Sales (P/S)0.00
P/FCF Ratio-5.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TripSitter Clinic Ltd Business Overview & Revenue Model
Company DescriptionTripSitter Clinic Ltd. operates a consultative virtual clinic and tele-health platform that connects patients to a licensed physician who can evaluate for a prescribed treatment program of low-dose oral ketamine medication in the United States. Its platform covers treatment for depression, anxiety, post-traumatic stress disorders, bipolar disorders, and obsessive-compulsive disorders. The company's treatment subscription plan includes consultation with a physician, oral ketamine prescription medication, treatment sessions with a licensed medical practitioner, and messaging with a licensed medical practitioner. It serves clients in California, Illinois, Arizona, Colorado, Michigan, Washington, Florida, New York, Ohio, and Virginia. TripSitter Clinic Ltd. is headquartered in Toronto, Canada.
How the Company Makes Money
TripSitter Clinic Ltd Financial Statement Overview
Summary
Financials indicate severe distress: revenue fell to 0 in 2025 from 13.98K (2024) and 488.30K (2023), losses are persistent, equity is negative (solvency red flag), and operating/free cash flow remain negative despite a reduced burn rate.Income Statement
Results show severe deterioration and lack of business scale. Revenue collapsed to 0 in 2025 (annual) from 13.98K in 2024 and 488.30K in 2023, with highly volatile growth (including a large spike in 2023 followed by a sharp decline). Profitability is consistently weak: net losses are persistent (e.g., -304.86K in 2024; -1.87M in 2023), and margins were deeply negative in 2024 and 2022, indicating the cost structure is not supported by the current revenue base. A modestly smaller loss in 2025 (annual) is a positive, but it occurs alongside zero revenue, which limits its quality.6
Very Negative
Balance Sheet
The balance sheet is highly strained. Stockholders’ equity is negative from 2023 through 2025 (e.g., -449.55K in 2023; -747.37K in 2025), which is a major solvency red flag and reduces financial flexibility. Total assets are extremely small by 2025 (1.20K) versus debt of 339.62K, highlighting a significant imbalance between resources and obligations. While debt levels were lower in earlier years, leverage risk has increased as equity turned negative and assets shrank materially.8
Very Negative
Cash Flow
Cash generation is consistently negative, with operating cash flow and free cash flow below zero every year provided (e.g., -1.76M in 2022; -1.39M in 2023; -201.59K in 2024; -46.52K in 2025). The burn rate has improved significantly versus 2022–2023, but the business still does not fund itself from operations. With ongoing cash outflows and weak profitability, liquidity risk remains elevated unless external financing improves.12
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 13.97K | 488.30K | 87.22K | 0.00 |
| Gross Profit | 0.00 | 0.00 | -4.70K | 138.71K | -554.60K | 0.00 |
| EBITDA | -4.64K | -9.61K | -348.48K | -1.85M | -10.22M | -177.59K |
| Net Income | -4.64K | -9.61K | -304.86K | -1.87M | -26.11M | -179.33K |
Balance Sheet | ||||||
| Total Assets | 598.00 | 1.20K | 2.83K | 99.27K | 1.46M | 780.68K |
| Cash, Cash Equivalents and Short-Term Investments | 598.00 | 1.20K | 2.83K | 54.85K | 1.30M | 772.39K |
| Total Debt | 389.11K | 339.62K | 273.05K | 133.50K | 133.50K | 17.88K |
| Total Liabilities | 816.44K | 748.57K | 730.57K | 548.82K | 197.59K | 93.36K |
| Stockholders Equity | -815.84K | -747.37K | -727.74K | -449.55K | 1.26M | 687.32K |
Cash Flow | ||||||
| Free Cash Flow | -55.19K | -46.52K | -201.59K | -1.39M | -1.76M | -92.97K |
| Operating Cash Flow | -55.19K | -46.52K | -201.59K | -1.39M | -1.76M | -92.97K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 2.30M | 0.00 |
| Financing Cash Flow | 53.66K | 54.91K | 139.54K | 136.43K | 16.16K | 865.37K |
TripSitter Clinic Ltd Peers Comparison
UnderperformOutperform
Sector (51)
TSE:KETA
TripSitter Clinic Ltd
0.06
0.03
120.00%
CGNSF
Cognetivity Neurosciences
0.01
0.00
0.00%
AIRDF
Rocket Doctor AI
0.55
0.10
22.22%
UDOCF
UniDoc Health Corp
0.11
-0.20
-64.52%
TSE:NARA
PanGenomic Health, Inc. Class A
0.53
0.32
152.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.